The FDA recently released its guidance on nitrosamine contamination and set deadlines for risk assessment updates and full compliance. This is an issue that affects no small portion of the industry: about 30% of approved active pharmaceutical ingredients (APIs) are susceptible to nitrosamine formation. In this article, we discuss the guidance in detail, look at various approaches for reducing the presence of impurities, and demonstrate how Adare's unique nitrosamine mitigation process can help products achieve compliance.
Please check the highlighted fields and try again.
Please fill out the information below. If you are already registered, login and this information will be filled out for you.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the phone number you would like to be contacted at.
Please enter the e-mail address you would like to be contacted at.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.